<SEC-DOCUMENT>0001816590-26-000021.txt : 20260324
<SEC-HEADER>0001816590-26-000021.hdr.sgml : 20260324
<ACCEPTANCE-DATETIME>20260324073020
ACCESSION NUMBER:		0001816590-26-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260324
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260324
DATE AS OF CHANGE:		20260324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPASS Pathways plc
		CENTRAL INDEX KEY:			0001816590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39522
		FILM NUMBER:		26784177

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT
		BUSINESS PHONE:		1-716-676-6461

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 1 ASHLEY ROAD
		STREET 2:		ALTRINCHAM
		CITY:			CHESIRE
		STATE:			X0
		ZIP:			WA14 2DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Compass Rx Ltd.
		DATE OF NAME CHANGE:	20200701
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cmps-20260324.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce808-3181-7c41-b707-3ef22510898e,g:b8c310e5-5530-499b-bc20-6dd12d01b687,d:5800d0d8aad74e9fa70a3fa7d90cfb90-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cmps-20260324</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001816590</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cmps-20260324.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-24</xbrli:startDate><xbrli:endDate>2026-03-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5800d0d8aad74e9fa70a3fa7d90cfb90_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 24, 2026</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">COMPASS PATHWAYS PLC</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Its Charter) </span></div><div style="padding-left:1.52pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:32.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.268%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">England and Wales</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39522</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(State or other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-6">33 Broadwick Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-7">London</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-8">W1F 0DQ</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-9">United Kingdom</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices; Zip Code) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">+<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-10">1</ix:nonNumeric> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">716</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">676-6461</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Former Name or Former Address, if Changed Since Last Report) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.008&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CMPS</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2.5pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operation and Financial Condition</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">On March 24, 2026, COMPASS Pathways plc (the &#8220;Company&#8221;) issued a press release announcing the Company's financial results for the year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits.</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The following exhibits are filed herewith: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.242%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q42025pressrelease.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q42025pressrelease.htm">March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q42025pressrelease.htm">24, 2026</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover page interactive data file (embedded within Inline XBRL document)</span></td></tr></table></div><div style="padding-left:37.54pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr></table></div></div></div><div id="i5800d0d8aad74e9fa70a3fa7d90cfb90_4"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">COMPASS PATHWAYS PLC</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 24, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Teri Loxam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Teri Loxam</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q42025pressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ibca46722238e4fbea255ae0828900bbd_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="margin-top:5pt;padding-right:-15.47pt;text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:307px"></div><div style="margin-top:5pt;padding-right:-15.47pt;text-align:center"><font><br></font></div><div id="ibca46722238e4fbea255ae0828900bbd_96"></div><div style="text-align:center"><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights<br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:13.8pt">COMP360 is the first classic psychedelic</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.42pt">Across three large trials in TRD, including two positive Phase 3 studies, COMP360&#8217;s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.42pt">Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.42pt">Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.42pt">Phase 2b&#47;3 trial in PTSD initiating, following FDA acceptance of IND application </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.42pt">Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028<br></font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">LONDON &#38; NEW YORK, March 24, 2026</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Pathways plc (Nasdaq&#58; CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights. </font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8220;COMP360 is shaping the future of mental healthcare, and we are moving the field of psychiatric medicine forward for the millions of people urgently needing better options. As the potential first classic psychedelic approved by the FDA, COMP360 is redefining rapidity and durability with response as early as the day after dosing and lasting through at least 6 months with just one or two doses &#8211; an unmatched clinical profile and important advancement for those living with TRD,&#8221; said Kabir Nath, Chief Executive Officer of Compass Pathways. &#8220;We look forward to our upcoming FDA meeting to confirm our NDA submission strategy, and we continue to advance our commercial readiness to be launch-ready by the end of this year. We are also initiating our late-stage PTSD study, reinforcing our commitment to advancing innovative, science driven treatments for people facing the most challenging mental health conditions.&#8221;</font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Business Highlights&#58;</font></div><div><font><br></font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">COMP360 in Treatment Resistant Depression (TRD)</font></div><div><font><br></font></div><div><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">FDA approval pathway</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Compass is scheduled to meet with the FDA to confirm the NDA submission strategy, including a rolling submission and review</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">26-week (Part B) data from COMP006 in early Q3 2026 is expected to be the final dataset for NDA submission </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Compass is rapidly advancing commercial readiness efforts to be launch-ready by the end of 2026</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">COMP360&#8217;s differentiated profile and commercial opportunity </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Of the approximately 4 million</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> TRD patients in the U.S., it is estimated that fewer than 200,000 (5%) of patients</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> receive an FDA-approved treatment indicated for TRD</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Across three robust late-stage clinical trials in more than 1,000 participants, COMP360 has consistently achieved highly statistically significant results at the primary endpoint and demonstrated clinically meaningful efficacy in a patient population that has historically been failed by other treatment options</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">COMP360 has the potential to redefine rapidity and durability for patients with TRD, offering a highly differentiated and transformative clinical profile unlike any other treatment available for this patient population today. As announced in February, the data demonstrate the following&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Extremely rapid onset of action with reduction in depressive symptoms as quickly as the day following administration at the first measured timepoint</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">The first pivotal, placebo-controlled trial COMP005 demonstrated extensive durability that lasts at least through 6 months after only 1 or 2 administrations for those participants in the 25 mg arm who achieved a clinically meaningful reduction in MADRS (&#8805; 25%) at Week 6 </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">A generally well-tolerated safety profile with a significant majority of treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the vast majority resolving within 24 hours</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Compass&#8217; strategic collaborations are generating valuable insights into future implementation opportunities for COMP360 within the current infrastructure</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">COMP360 is expected to fit seamlessly across diverse healthcare settings within the current infrastructure of over 7,300 centers</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> offering multi hour treatments</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Treatment centers are growing rapidly, and existing centers are already scaling in anticipation of a COMP360 launch and additional psychedelic treatments coming to market</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">COMP360 will potentially offer a highly differentiated, patient friendly dosing schedule, compelling clinical profile and is expected to be a blockbuster opportunity</font></div><div><font><br></font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">COMP360 in Post Traumatic Stress Disorder (PTSD)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">FDA accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of Phase 2b&#47;3 trial </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Previous Phase 2 open-label, safety and tolerability study in PTSD with 22 participants showed COMP360 is generally safe and well-tolerated, with no serious adverse events observed, and demonstrated both rapid and durable improvement in symptoms observed following a single administration of COMP360 out to 12 weeks. The results of this study were published in the September 2025 issue of the Journal of Psychopharmacology</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Affecting&#160;13 million people&#160;in the U.S. each year, PTSD remains an underserved condition. There are currently only two FDA-approved medications for PTSD. This limited pharmacological landscape underscores the urgent need to advance care for patients experiencing this debilitating condition<br></font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Financial Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Research and development expenses were $29.9 million for the three months ended December 31, 2025, compared with $32.1 million during the same period in 2024. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decrease was primarily attributable to a decrease in personnel and non-cash share-based compensation expenses due to decreased staffing levels associated with the reorganization that took place in the fourth quarter of 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Research and development expenses were broadly stable at $118.4 million for the year ended December 31, 2025, compared with $119.0 million during the same period in 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">General and administrative expenses were broadly stable at $16.0 million for the three months ended December 31, 2025, compared with $16.3 million during the same period in 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">General and administrative expenses were $60.6 million for the year ended December 31, 2025, compared with $59.2 million during the same period in 2024. The increase was primarily attributable to an increase in legal and professional fees primarily due to issuance costs related to our January 2025 Financing as well as expenses associated with consulting, accounting and legal advice, partially offset by decreased personnel and non-cash share based compensation expenses due to decreased staffing levels associated with the reorganization that took place in the fourth quarter of 2024 as well as decreased facilities and other expenses as a result of lower insurance premiums and banking fees</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Net loss for the three months ended December 31, 2025, was $93.9 million, or $1.00 net loss per share&#58; basic and diluted, compared with $43.3 million, or $0.63 loss per share basic and diluted, during the same period in 2024. The increase in net loss for the quarter was primarily driven by a $38.2 million non-cash loss on fair value adjustment related to our warrant liabilities, compared with $0.0 million during the same period in 2024. As the fair value of the warrants fluctuates with our share price and other market inputs, this adjustment can result in significant variability in our reported net loss</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Net loss for the year ended December 31, 2025, was $287.9 million, or $3.08 net loss per share&#58; basic and diluted, compared with $155.1 million, or $2.30 loss per share basic and diluted, during the same period in 2024. The increase in net loss for the period was primarily driven by a $122.6 million non-cash loss on fair value adjustment related to our warrant liabilities, compared with $0.0 million during the same period in 2024. As the fair value of the warrants fluctuates with our share price and other market inputs, this adjustment can result in significant variability in our reported net loss</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Cash and cash equivalents were $149.6 million as of December 31, 2025, compared with $165.1 million as of December 31, 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.05pt">Debt was $31.6 million as of December 31, 2025, compared with $30.2 million as of December 31, 2024 (and $50.4 million as of March 24, 2026)</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Financial Guidance</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The cash position at March 24, 2026 is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.</font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">About Compass Pathways</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass Pathways plc (Nasdaq&#58; CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.</font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Forward-looking statements </font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as &#8220;may&#8221;, &#8220;might&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;objective&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;contemplate&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our expectations regarding our financial guidance&#59; our business strategy and goals&#59; our expectations and projections about the company&#8217;s future cash needs and financial results&#59;  our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment for treatment of TRD or PTSD&#59; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD and our phase 2b&#47;3 trial in PTSD&#59; our expectations regarding the time periods for the release of data from Part B of the COMP006 Phase 3 trial for TRD&#59; our expectations regarding discussions with the FDA, including discussions regarding potential NDA acceleration strategies, including potential for rolling NDA submission and review for COMP360 psilocybin treatment in TRD&#59; our expectations regarding timing for our NDA submission&#59; our expectations regarding potential commercial launch timelines and our commercial readiness&#59; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all&#59; our ability to obtain regulatory approval and adequate coverage and reimbursement&#59; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained, on an accelerated timeline or at all&#59; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment, including as a treatment for treatment of TRD or PTSD. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass&#8217;s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">These risks, uncertainties, and other factors include, among others&#58; uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected&#59;  the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date&#59; our need for additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials&#59; our acceleration strategies for our NDA submission may not be successful&#59; FDA may ultimately disagree with our proposal for a rolling NDA submission and may not permit us to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">utilize the rolling review process&#59; our efforts to obtain marketing approval from FDA or regulatory authorities in any other jurisdiction for our investigational COMP360 psilocybin treatment may be unsuccessful&#59; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful&#59; the risk that our strategic collaborations will not continue or will not be successful&#59; and our ability to retain key personnel&#59; and those risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in Compass&#8217;s most recent annual report on Form 10-K or quarterly report on Form 10-Q, the prospectus supplement related to the proposed public offering we plan to file and in other reports we have filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which are available on the SEC&#8217;s website at www.sec.gov. Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass&#8217;s current expectations and speak only as of the date hereof.</font></div><div><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">References</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1. For the definition of classic psychedelic, see Vollenweider, F.X. and Smallridge, J.W., 2022. Classic psychedelic drugs&#58; update on biological mechanisms. Pharmacopsychiatry, 55(03), pp.121-138</font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2. Data on file </font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3. Data on file </font></div><div style="margin-bottom:8pt"><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4. Data on file</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#0a94d0;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Enquiries</font><font style="color:#000000;font-family:'Aptos',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br></font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Media&#58; Dana Sultan-Rothman,&#160;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;compasspathways.com</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><br>Investors&#58; Stephen Schultz,&#160;</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">stephen.schultz&#64;compasspathways.com</font><font style="color:#625d5a;font-family:'Montserrat',sans-serif;font-size:10pt;font-weight:400;line-height:133%">, +1 401 290 7324</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ibca46722238e4fbea255ae0828900bbd_4"></div><hr style="page-break-after:always"><div style="min-height:58.32pt;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">149,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">165,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41,503&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,821&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">191,490&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">201,291&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT ASSETS&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,424&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,006&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,751&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term prepaid expenses and other assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,684&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,595&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">210,349&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">213,666&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS' (DEFICIT)&#47;EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,283&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,214&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,495&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,523&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,513&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">203,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">247,795&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">NON-CURRENT LIABILITIES&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Debt, non-current portion</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,110&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,652&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">263,197&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,971&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">SHAREHOLDERS' (DEFICIT)&#47;EQUITY&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares, &#163;0.008 par value&#59; 96,085,785 and 68,552,215 shares authorized, issued and outstanding at December&#160;31, 2025 and 2024, respectively</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">783,562&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">704,919&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(14,789)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,194)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(822,594)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(534,732)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' (deficit)&#47;equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52,848)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">154,695&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' (deficit)&#47;equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">210,349&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">213,666&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:161%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ibca46722238e4fbea255ae0828900bbd_7"></div><hr style="page-break-after:always"><div style="min-height:25.2pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMPASS PATHWAYS PLC</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(expressed in U.S. Dollars, unless otherwise stated)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.887%"><tr><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended </font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended </font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,906&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,141&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">118,436&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">119,039&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,046&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,273&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60,601&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">59,166&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">45,952&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">48,414&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">179,037&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,205&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">LOSS FROM OPERATIONS&#58;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(45,952)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(48,414)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(179,037)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(178,205)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OTHER (EXPENSE) INCOME, NET&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value change of warrant liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(38,163)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(122,561)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Expense) Benefit from R&#38;D tax credit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,912)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,097&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,182&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,268&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,137)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,517)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,479)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (losses) gains</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,926)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,032)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total other (expense) income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(50,660)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(111,298)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,677&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(96,612)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42,309)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(290,335)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(153,528)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,023)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93,878)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(43,332)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(287,862)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(155,122)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders&#8212;basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.08)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ordinary shares outstanding&#8212;basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,636,285</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,395,343</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">93,504,836</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">67,482,902</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93,878)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(43,332)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(287,862)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(155,122)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(93,480)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(42,984)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(286,457)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(154,390)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:187%">7</font></div><div style="margin-bottom:6pt;padding-right:18pt"><font style="color:#625d5a;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:187%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cmps-20260324.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce808-3181-7c41-b707-3ef22510898e,g:b8c310e5-5530-499b-bc20-6dd12d01b687-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cmps="http://compasspathways.com/20260324" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://compasspathways.com/20260324">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20260324_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmps-20260324_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://compasspathways.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cmps-20260324_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce808-3181-7c41-b707-3ef22510898e,g:b8c310e5-5530-499b-bc20-6dd12d01b687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019ce808-3181-770e-8be0-57915d9d5820_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019ce808-3181-7f8f-87c9-da3c65b92066_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019ce808-3181-7d14-aedd-4f0ebdde96ca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019ce808-3181-7415-b58f-dd6a479927ae_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019ce808-3181-7d2f-acc4-994259142de3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019ce808-3181-7962-8405-e7fc7aeaebde_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019ce808-3181-753d-acc1-bde95180413f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019ce808-3181-7ca5-8440-c565f6a87c8a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019ce808-3181-7a8e-a6dc-0ac5721a94dd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019ce808-3181-7063-afb6-9d1a35dc5cba_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019ce808-3181-7985-95f2-2eaa758d69ef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019ce808-3181-735f-8a10-b45a2759490b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019ce808-3181-7eb7-aee4-f3f5f34fb2b3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_019ce808-3181-71c2-b0d7-dd5cdded8d6e_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019ce808-3181-78aa-82da-0489ad6d666a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019ce808-3181-7143-8a0a-8bedf3a3bc79_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_019ce808-3181-7b80-ad33-90e3adb2b2e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019ce808-3181-7dcd-a12d-a0bd8de8073a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019ce808-3181-717c-b847-c16aeea849b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019ce808-3181-77c1-94c4-c885d0d7b2c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019ce808-3181-7115-b499-af4c28749954_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019ce808-3181-793f-8a3e-e3dd50f8ed34_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cmps-20260324_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ce808-3181-7c41-b707-3ef22510898e,g:b8c310e5-5530-499b-bc20-6dd12d01b687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://compasspathways.com/role/Cover" xlink:type="simple" xlink:href="cmps-20260324.xsd#Cover"/>
  <link:presentationLink xlink:role="http://compasspathways.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ce808-3181-7524-bf79-b00e72f5f7b5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_DocumentType_019ce808-3181-7524-bf79-b00e72f5f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ce808-3181-7f64-ad22-5193dc42ba57" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_DocumentPeriodEndDate_019ce808-3181-7f64-ad22-5193dc42ba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ce808-3181-731f-b335-4fefd68257d8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityRegistrantName_019ce808-3181-731f-b335-4fefd68257d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019ce808-3181-7018-9a30-60af6737e8d9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019ce808-3181-7018-9a30-60af6737e8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019ce808-3181-7dc2-9336-8e6cba743471" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityFileNumber_019ce808-3181-7dc2-9336-8e6cba743471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019ce808-3181-7c93-b550-b0e6b2e1d12b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityAddressAddressLine1_019ce808-3181-7c93-b550-b0e6b2e1d12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019ce808-3181-70fa-8d73-e7c83272e914" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityAddressCityOrTown_019ce808-3181-70fa-8d73-e7c83272e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019ce808-3181-76dc-bfc2-56bdfb40212b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityAddressPostalZipCode_019ce808-3181-76dc-bfc2-56bdfb40212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_019ce808-3181-7277-a063-4bc699cd2c6d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityAddressCountry_019ce808-3181-7277-a063-4bc699cd2c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_019ce808-3181-7643-ae11-ddee3662d98f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_CountryRegion_019ce808-3181-7643-ae11-ddee3662d98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019ce808-3181-732e-8b1d-4e3760f5710c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_CityAreaCode_019ce808-3181-732e-8b1d-4e3760f5710c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019ce808-3181-746b-a584-9f73a57b5b21" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_LocalPhoneNumber_019ce808-3181-746b-a584-9f73a57b5b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019ce808-3181-7eba-b5d8-9fc927d01a0f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_WrittenCommunications_019ce808-3181-7eba-b5d8-9fc927d01a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019ce808-3181-7fad-8ed3-ea03a3e2dc33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_SolicitingMaterial_019ce808-3181-7fad-8ed3-ea03a3e2dc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019ce808-3181-7ae9-8a3c-769b29059448" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_PreCommencementTenderOffer_019ce808-3181-7ae9-8a3c-769b29059448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019ce808-3181-7adc-9e2e-8f92d7aabc07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019ce808-3181-7adc-9e2e-8f92d7aabc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019ce808-3181-7350-836e-e234cff0ad90" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_Security12bTitle_019ce808-3181-7350-836e-e234cff0ad90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019ce808-3181-7bd6-99f6-19d08a520455" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_TradingSymbol_019ce808-3181-7bd6-99f6-19d08a520455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019ce808-3181-7a6c-b193-06e1a9b39539" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_SecurityExchangeName_019ce808-3181-7a6c-b193-06e1a9b39539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019ce808-3181-777f-9bec-b7fc98076d0f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityEmergingGrowthCompany_019ce808-3181-777f-9bec-b7fc98076d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ce808-3181-7799-98a6-09233222ef76" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_AmendmentFlag_019ce808-3181-7799-98a6-09233222ef76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ce808-3181-7bbb-a0b2-4f7ff10f0aca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ce808-3181-7db8-913e-b536fd3047f3" xlink:to="loc_dei_EntityCentralIndexKey_019ce808-3181-7bbb-a0b2-4f7ff10f0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MQZBC:?H.REX\*C]2^16](XD:%\AP>$[^^YE4B%-"'Y/H!L(PV@N=ZTDJ*C3
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MXSI"OD*%"N/%<S#(]!>HIL:* TGTW0]+?(4*SP[4Z_6_3D_IS87*:ZI08;.
M,=$^G'JGH?(S(]$0+V6=^+4.%2I4J%"A0K<0!+/_1NOH&!JJ4+FU,%2\#VFS
>N,JCPK,!VVSSOY6/C?/]M@A8     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 24, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 24,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COMPASS PATHWAYS PLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">33 Broadwick Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">W1F 0DQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-6461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.008&#160;per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMPS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cmps-20260324.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://compasspathways.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cmps-20260324.htm">cmps-20260324.htm</File>
    <File>cmps-20260324.xsd</File>
    <File>cmps-20260324_lab.xml</File>
    <File>cmps-20260324_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cmps-20260324.htm": {
   "nsprefix": "cmps",
   "nsuri": "http://compasspathways.com/20260324",
   "dts": {
    "inline": {
     "local": [
      "cmps-20260324.htm"
     ]
    },
    "schema": {
     "local": [
      "cmps-20260324.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cmps-20260324_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmps-20260324_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://compasspathways.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20260324.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmps-20260324.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://compasspathways.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001816590-26-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001816590-26-000021-xbrl.zip
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M#Y WB(PVK&].Y^W+>I4V&,?Y#?L5'2[8[OYL";UAM]G+R6]02P,$%     @
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M39*YV0FV9J#ISJ])TF^=7I.]WH="<T9Y%?E^?K)])EO_U\;SD_\#4$L#!!0
M   ( ,D[>%SS4:H1V 4  )PP   5    8VUP<RTR,#(V,#,R-%]P<F4N>&UL
MU5K?<YLX$'[/7\'Y7D^QD "A3)-.SDUO,I>VF22==NZEHQ\KFRD&CR!U\M^?
MP'$;&Z=E##.F+[:!%=_NMY\7:<6KUP_SU/L&MDCR['3D'^.1!YG*=9)-3T<?
M[]ZB>/3Z[.CHU1\(??[[YLI[DZO[.62E-[$@2M#>,BEG7CD#[U-NOR;?A'>=
MBM+D=H[063ULDB\>;3*=E1[!)%J;K:_:$^QS!3&.$?5C'S$5^$@RS! %0TCH
MXYC'\-?T1,:*^AA"%(84HX!SB:0B&$5:^T1C7T8QJV^:)MG7D^I#B@(\%UY6
MU(>GHUE9+D[&X^5R>?P@;7J<V^F88$S':^O1D_E#PWY):VN?<SZNKWXW+9)=
MANZV_OCSNZM;-8.Y0$E6E")3%4"1G!3UR:M<B;)F_9=^>2]:5$=H;8:J4\@G
MCLGCAT*/SHX\;T6'S5.X >-5WQ]O+K]#JGR^$$6Q$.5L*1Z+8W<\KFS&D]QI
MPGE;CRX?%W Z*I+Y(H7UN9D%<SI2\T6!JK1B2H(*\\_5P/$/Z(6%PNFE#O7*
MG7@:7Z'LY08\E)!I6$6W!DESM6&45MSFWT>F0D):G_VB(?E2W_5<%J45JORR
MI3\M8\1]"DB&-#*:XH 9NAEUY77AW*Y348 ZGN;?QN[&+B4DK'Y4E(0U'0VX
M%37[^;W^[]TYVVVW0Q(@:1A'$F-@Q(2&R;"3V\_1-KU^GM)SJ[S<:K"N>*SA
MA%4;Z6W*]LEBO!#6W0BI69+J]6AC\WD?N2KS'IA;I<6Y._)<U :L!7VURLJ+
MP=61E:ZD0FW91\:OP2:YOLCT&U=SMP,P48"$)@2%/J=:!42*D/62^@W85AH@
MP]? _EP>6 P769F4CS<P32HFLO*]F#?\I[Y!DM(0!0:,CF(2,AUWTL(NU%92
MH,.50F<F!Z&$2S=/LXO<UL3?.OYADM]GI7V<Y+H1#O8=-\+-G"(L3,0H@UCS
M'H3Q4R=:Z208ND[ZXWD0LGF;I/#^?B[!-GA1!'%*(Q1#I*1@ 0V8WX-&?B"V
M$D0X=$'LR> @LG^NM6.]>/IR$W+PMX-0G#HB0NPF1!!) KY;8,D>9+ #NI4>
MHJ'KH2NG0Q+&Q/W\8._R9=:H;$:@6#.*@*F8$D: ^T%_LO@!W$H4[#<1Q9Y\
M#DD2UWE1BO2_9+'K>1=IY59/KNR%D=1&!ICT6BPVL%L)(_Y-A+$_JT/2QM-,
M:-M_PA@2.*(HD"KB7&FB(MUCK5BAMM(#_TWTL ^3!U;"D\O5.BIOE+<HH$B
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M]NPX2DEM#E9;MLB4XXATV$FN:!4J^)HZ-BEI .(QS V;!2;"8Q32:A&(.'R
MR_,C\OKAV["05!U''&570Y+6 KYC;3BH,!TF:M _LP0U/#C>F(P&&$$DC"P#
MZP@&8EDXXBGN9:JOY_8!3B-'B+!H(2KU0Y#*J$X6AF*!)*#07&BC$*AAY(1+
MG_T*^XO9&4?\?P.*_H"=?A5>1D;+QP$8KGCB S9/LTVF$>8SC!]%7PJ  LD!
MR;!L#,2:"TE4<ND<IJHM/C.GE)*I(JXF!4+!L_!:)HC*U<[HO:6J%3S3%UH9
M:N#7DQS6P.EQ!^D0X(QDVV2?%;*"V1:51#N-'< 2&F!N@V%'DA_M-5A1+&0(
M._3RQW )4MGGQ>*4-%+LY1K((O$D,A[FQ_"Q9-$G!!J-Y /NY00SBA!YAV#'
MB_ *OYPA-3P-7RK,UP!<8"=;=/^M)XJ6^.J(@:]8V7(?Z*.ONJ![,-D+-\MY
MX68YF7.S/'PSWU(;("64N!MR!46=554[=^LP73;[G-KI-DUWSK)+D.]F@=(U
M;K76E]C94Y8V=0O=8<?7L'L@[.PVO"2^L(-/H+*QGU^!:$XY&\31B 2^:;:1
M\)7P_LU103B9:(-<@;DOM 83 DWAZV!O$].> ^]*6)4#;(ON[54A-ZW^F=-7
M>#^)@BQ=_<JZ4;J58:DU8B*7<@3JR)FX8>?1B(< LHVAU;;^4?+8WQ;(0EU(
M#B9W1175O\-X>@Y7H.$#,__2("WLD >HI;RH2NBS)MZ-&>^:+C4Q ,),U]#_
M;K6*%^!S>]1VE=EVM-DXCZXLK!ETH #5]+"C,=H768A64"V>'HCA'P>$E*2R
M?95@UPG \59N_W[[$.SRI=XK!&OOY%Q?O)X-=6&P% [T]^9%$]2LE&0YR)"1
M\@]A/&L@;@3:PF!)VZ9I@(!C!^X_7I&K08^R5^?N[.K<8^$)] O 08+NVRB<
M*M-@-9"[]LSID&3-+Q[(+V8BSG'41U]1R4E1.(2F8>A1% N%[1;A^I@C'LDQ
M>KZG3B\,\B[+8_#736.@X!/YWV(@MGB"<G8<R3"="SZ+6Y(=X$L//>]@%.6>
MVW$TS@+EH"V"T4-81Q3K$2@F/> R4-Z\")80ES!0>P=KO'NH)E;"DUDO*VA:
MVETJ;DU(*#ATX7@$C@OJAC*"-9;-:2 X#"!-F,  (^*(BR[/+ SD%V1"B\#G
MUX 7O!\([?T$6; ,K]#-3^YCKK/5_'(8R= .7; :2UBLHP$Z]K?<R[44Q\C4
MJ'%L&8Z=?@70C5 !(CQBZ%E/42QSCP"E7>Y^YN4!FSP%"O BF8S&H'8GZ('_
M*Y/>EUEG_#1,RWTP_*1*A$%72UK*@@-VE&0QBC P<HE[U4!](% OB\,=R^LH
MY8&!:0^>Z$<-=.BC\XM4!F0ERB'CSDH+"LX2B$L,A60!QE.2:10E#ZL4T105
M@(E"P 0+@RGV'.R34E"D+!5S'=)V&28:QR-V,XRF I&O$& SF/GA^.3\@AT
M0+JF>P1#@8()*_V,KJCVFF93C56KU:#528Z8X @8DHL'G1-95EA&_$]0'^ 9
M# /EPJ(!G(<BC.AAH 0; #8BP\'EZ?%I\@H4#0K"2(QBQH!B/LV'L$XP.0[&
M4Y$JQ)QKQ,=B&F!145#$W. %N\6&41;76LF6_$/:@9'[UZ4'JFP @C_*Z1S#
M>PIA*+)WS8.,U ()C 6C5"K;0T>U)2;*4;"-B'GJ[I!"<8QIDA9!$P'N97&L
M#)Y!#+"/@1%DZ^9&UF1^I]8YYY#?/#'N3E A+X@PQ[5C.& D*:?X?OD!6KOR
M Q1J_ CL0$FLK13>KHG@H1I48<]HK%3L+%;JK/:+Y_F^4J68E)_D@?)_)X T
M.D4.I" I.XK!@8)=\#3E,:?!<#'X -I:I=R94N*"SNG 2"B/OXA:6=X6OZ/T
MW\+$#B:*Q%:9R49AU0YB^!]&273641ZM-BA73J@X\_*DH860)V?](/*^H(>)
MLJP*I__>9'-\P@R:RYAGZ#KPV$6*MB([D4D4@_+&#C"C9S&=H];!-L/9:=IS
MPMZ%U^ALO^*:;V"4^"3.KMC!N[.35^RXE M=5J3RK+^2VVZ M3)I(RV@ERCH
M^;/0,Y@(09-3;$UE;BF.MC1_NX;U V']"9-2HBS)CQ?8@@@;H&D+,.NUX44V
M$%ECVE:GG+DB=Y[L,=N>-;B3870#C*>D[DW-.RI84RF 93M/5[N%$<,-XIKF
M[+:H#S]<XX,+#NA^A(XD\C$5CLJ %'\,8.C(Q=2CE(]4=B(QY*_(.V>]29@:
MJ3<1990,:-D,\T^2)D-/2.XKSQ,0U=G< "]GXPSP.!DJYR-2PP60E!CUA4XL
MEDF2"?6B8/\&'0L)##$=97,T'O)XQ#U*C*[1_*'>!:I^([^NU3:/+*>H&E!I
MFNKK4J21"0Y*$V:3&@K+8S'BDFI[6 :G&VL$*I(V"1MBE7>J#1*4\NBJPI3?
MF7#:2*6W%PXKG #?!_0)Y$A2I'X*?9+L : UJ'MCH6?W(D \6JW*HJ8<ZG(>
M+5E+,UYZU 90F]#YJ#"9+XB@E0E=[*0:4G]:.UXJ$Z_)X&%D<"[ R(ZU->!C
MC6@T)N:(N!%B4CHQKI=VK]F;EN+DLIPBE-H3"THIX-N)\!0_<RRJ2G&56LK1
MX4[,_*5C-ZUB)&#+>2YTPD? ()'/$W>$=UN*G]8I=YNDW-DKC^L9IMP]/HG[
M CO!@(9RPQ,=)I?HODI!.^UG*>D@R)-9\:!$B1,G41B*@*@PC,(&5:DEP/'S
M(B:R[<)$:2 %;?JJ4B(?R\<(_F" %$7EWA@H2R)/Q5F+'.981/$5#^7?I9![
MBO4<%+/)-9.Y*BB53;>- N+;\^MJOKU5OMV/(^ZKS [$/(#T2\OJ-EL+K)R*
MV]9EX9;5:YIK\O :8RJ",?]2UI9V^TTMFFNQ!LZT2_!^D/2'D9P:<YXHYKQL
MF\WVPUB+VVO:&VF',EQ/X(;3)^']0%SI#:&#5)5^836I$.5!M'A%JUQ94!$F
M(Y"&*8JRQW_SD"K1R_VMT'N0D#.#JD;S0YJ7QIB,A^$4[#' /2_*PK2H(U4+
M]*^E)PSE2,F=Q)@PTY^4A/YMZ@.KE/I0/I7IK%@0&:C0*VY 97B5#@WKIU0;
M)1@FB#"S%^SN+":8C,$,E]E(EV#S\ LN'^%8LX^*L(\SP-< @[>;"0ZDYY<]
M9VIV&IB3\=)JFB8+\R$!]16>JR8"@.Q8^8TJD42+SE_@+RUG*G_4@,"RG+G!
MEHVS$2^";\/Y7>>D,,NG=*4PT#,'T[A;8GX%'=,H$27 QI36@!Y)M.!TK[ 9
M;J3[7;! *M<L-9Z:.P-S;>6M*+@OS:V]DT5CC4& T758@\[ZQ%6H4X1=>J)$
MTBJ "&./,TQ+)H=3:2<>\&A-Y^B9+27S7,-9Y9YF^ EG*#HVY.=<DWM5R?UV
M^4]D;G<[\W3N-,WN ^C<<MVIFTF-:#<=\S$(7;]P"YU;MEW2DVI"KPE]'PG]
M#>(LU0WB'^*O3 +>J.Q_,@:L5J^$Y9P"8NL8B"7"7?%6;1I6!0=.1#]5+-RQ
M[@%LQRPI/"M@S0X0QUZZ9LEKI1Z=;7^U09;'&A6Z%<ETF<:\_I5)'PV>*C>4
M0M%(S" /K:#S:!9*2Y*0D@RKPJ1NK#/(4(R,\S3>J1E(C&8LL3T.?>E+RNF,
MD?'$8J0+0W5#M^;N07?<Q^R ^29*50;?FDW:$(2/VZ:M:-\TBE(0,NFTJ5<>
MXQY(M/Y5LS!:.GPW%,%894R.QN0TT/V7B/7D"26K&BZI<A"8,HQ2&DG-621?
M3C,DB\6-X3V1U[J%XJ8.7&X4N'2><>"R L0/8IG[\FJDS!C$[MOZD<%37H94
M"]2ZF&25M\Q+BGHM*M$K1:DP$S]#-]YL+F&>5Y5,0G@CI8Y^,HB\2;_<']V8
M29OENO0,GJ V@-/GFC.5SS\C^//U8&8.'R._0O-#9RMBOR#*]KE@;Z-(;8DR
M&X]G$\ .WIX<OZ)?<5Q=(>^S=T4C./8>[*&PZ EXK%B>9JOLX-W[XT^O9J;.
MTXQ^G9X^U2NM;@2_*. JA$NEEBYXC8GV?*FLM_> 0VB1__ZKSNZ+J.,@%>0A
M$_DCBK\4YW%!S%6$UU*US&(W41R \DAY5;.XB45Z"7%KZJU(#3?ZB=!=>D%O
MI-8Q_2S_2=<81HBB +(** QO53O%!O96I,3N%"2=TFNJ#&Q*4B/D1!<%>46P
MZ)-2XP:KMU2JUM'UE;G#X5-,,IY=""^+55C@O<R9!#O'CO0CH"EB(E:O!U8%
MA@A&Y&%J A6R)!J1'HH>D5M6@&X(4#]1"0&9(K52(6*@=:74)!G&UY.\[>6(
M3W071J/X"L]A_DM,[)__SHNRP%]X<-F7R7#9MTIEGO\6U%W8]?RWV'%\_KNH
M_R=F.UZ+^1^**I&%7_HBP%K8Q9W I*-QL.2-O ?+PH)BU H75E\P\6538!/0
MO&DI\M!\'^%5A.&R_"?M<@O%E6*\"H4 !1&."?ZL/%+*[E3!P"F$#;QA:$@"
M 1D'QW[LM^"+PFH] 7 B'W2_6XA6]?^C&"E1!RP&RPZEBK/E3RFUCRIL8#FC
M".E M3@88E6;,?OL%<PE=4-2A1,Z:73VIVF#XBMM-H+^WCNBWXHVQ7FG0CK?
MJX@'R?2AF;%UF)0PB#Z394-U=DKM+YI+Z>I*L@%1-5?O+K1+5O/<M@GEIJ1<
M<SBVHFW('6K#<F6AU(<1#9=I <*,K,6QL<F03KZ='L5\ _^E!S[7DZ4\*8VA
MKP*9N3A$.4R+7Y?WH5\!DMF3PDX&VJ$[=4/GS!CV-6V'J!HDYIPV;X[XJ;R\
MO(W/G3/[,@$=,%'64JE!9GGSY6>F;TX;BYSIPA)E)D[;9Y(W>SI,J=\S+"YO
MICG7FG':4'.F\&094F@(W'VXDHK?<+C%[L5WOCU==:FSFBZ^0Y"A+$T*+%C6
MZDY-,=?Q.@\SJ%8+!6X!A5[%?)0C%V@V248%7;@B[(,2Q1,@Q8!J92F50[>0
MI9@##Z=P0$G(0?%$6N#$%J=;+2E.49_886GTHBFMRA01?V&T #9V#:->"0T@
M.>IG<4(<;>FPU M&3C7R:2L&W?^(TB>GIZ6_G4E*(&I5"?[7V&LDKW@L'S(L
M%7LY )H-ENX!]T\[Q*#0X@GE )P_I!R<MY!K7X1B(%6%R".Q,Q6VND6XD5Q;
M4.3( 2(DR2,X%D!\@3IV#&*%8U!(()GBCB=1QI3F0I)4I8)D(2:8P%A2]?'.
M1><MR^@+CV<)==[!"-!U%(!0_Q)&-PJF6:C^CF7R!6;&/CXQ@DA%OZ8!J 'W
M )CPU8A:!@W 8I (?XSXB0E8(&RVJX 2[L!75!$2/4PJ&U/+X1CX*L27D:?'
MZ+8UU]07 O@O=3"BK<9Y*Q&U+4RRH7).AOI1K Q7;6]B9Q*M(@B_K"0H%]>M
MYU5I*_"2%K\FJ')M:48'4IW%9]]=R$FB"<K1T4(6EQT."J;DN<1>Z^EP4HAT
MU7@&T)NL=!JSF!$KO(!GY$O&1=&-6,N$/L 66Y7!M &?*% J7;-H<Z4?H&YM
MF$L63%33MMPAKO4B=?M",'N[A-:&IJ(<5Y +[B4MX9#X<3XDQ[XHWP16R.HQ
MDB:N+YX44R&FD@J?<V;RL")K*96*HX]>%X7G5^'-:):D3*J2XT%^3406YJEX
M6FX0N\E' HL^I*GT245A?LU.KK(#!.A^ "3*/M&$I\!-QVVH,JF9,U\&HY+$
M6:YUK)#UY:-,B@MJU&ATW0'\C)E\NKDGJ#W\"I.<BD YH-<X2K3XYK>I,/E,
M8]Q'RC*"2>U*WL25O#H^7+N2'X'Q9RDH<W^K]GDYHFO%7'/9DNH\[>6L^8)*
M'B'])E?%B-\AF:'R7U+5,I">VD-$#2_R[H!_9B 4T.60IR%OJF7EG#H+YXE]
M;LU3?1(W3)Q+[6*UTGNO!9&6FE>+&JN71T<. E&EY5*&SJI^2=1_ AE-<><*
MK*OX<@F?RS7;DJX>"]KL%U#6BB3DZ<-*MU'R66EO93GNB\2+91_OS,;Z55KZ
MD R?J]S;<XX[>:L4A-SC ]/-ZVYTBPJZX:D1::@T-;)\ /QOT5MHF8U?<7O:
M$QU,ECSPFZ&%8I2@- :^B_:3ZA)55B_T0\ Y,?4:"[J]:7<<$%'H+U AR;SM
M1JC14LV)Z3%LR*\%/5%*K*8BXY+3$]\]_>J!@@!H] 9OG]'^?WTZ%Z=O]*'@
MM;"%@CMMB!GI&G/U'!W5C>@#PZ>BCIN;FV8BO.95=-W$>4#8,@IG4#R=U,^
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M     &-M<',M,C R-C S,C0N:'1M4$L! A0#%     @ R3MX7 A-A:QE @
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F<')E<W-R96QE87-E+FAT;5!+!08     !0 % $@!  !>2@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cmps-20260324_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cmps-20260324.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816590</identifier>
        </entity>
        <period>
            <startDate>2026-03-24</startDate>
            <endDate>2026-03-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001816590</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-03-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">COMPASS PATHWAYS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39522</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-6">33 Broadwick Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-7">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-8">W1F 0DQ</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-9">GB</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-10">1</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-11">716</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">676-6461</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.008&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CMPS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
